Sobi Revises Full-Year 2025 Outlook
Swedish Orphan Biovitrum AB (publ) (Sobi) has made significant adjustments to its financial outlook for the year 2025. This revision comes as the company responds proactively to recent developments that have influenced its business trajectory.
Financial Reporting Schedule Update
In a move to maintain transparency, Sobi announced that it will release its third-quarter financial report earlier than previously scheduled. The new release date is on Monday, October 20, 2025, at 08:00 AM CEST. This decision underlines the company’s commitment to keeping stakeholders informed and engaged regarding its business performance.
Quarterly Performance Highlights
The group revenue for the third quarter of 2025 has reached an impressive SEK 7,776 million, marking a robust 21% increase when measured at constant exchange rates compared to Q3 2024. This growth can be attributed to the strong market performance of several Sobi products, particularly Altuvoct, Doptelet, and Gamifant, which have contributed significantly to the company’s revenue stream.
Improved EBITA Margins
For Q3 2025, Sobi posted an adjusted EBITA margin of 47%. This result reflects effective cost management strategies, including lower than expected R&D expenditures and efficiencies stemming from organizational changes made earlier in the year. The company has taken decisive steps to realign its SG&A and R&D activities, especially in light of the FDA's forthcoming review on the NASP biologics license application, anticipated for mid-2026.
Year-to-Date Insights and Outlook
As of Q3 2025, Sobi has achieved a year-to-date revenue of SEK 20,417 million, denoting a 15% increase from the same timeframe in 2024 when adjusted for exchange rates. The year-to-date adjusted EBITA margin stands at an impressive 40%. Given this performance, Sobi has revised its revenue projection for the full year. The anticipated revenue growth is now projected to be in the low double-digit percentage range, up from an earlier high single-digit forecast.
Research and Development Updates
Moreover, an impairment charge of SEK 6,612 million related to the product and marketing rights for Vonjo was recorded for Q3 2025. While this charge is significant, it does not impact the company’s cash flow and is noted as an item affecting comparability. Importantly, Vonjo remains a focal point as Sobi sees it as a crucial growth driver moving forward.
Regulatory Advancements and Market Potential
In regulatory news, Tryngolza (olezarsen) has received approval for the treatment of familial chylomicronaemia syndrome (FCS) within Europe, and its positive topline data for use in severe hypertriglyceridemia (sHTG) was announced in September. With approximately 700,000 people affected by multifactorial chylomicronemia syndromes across major European markets, Sobi sees considerable market potential, potentially exceeding SEK 5 billion.
Future Plans and Developments
This promising outlook is further bolstered by Sobi's plans to submit regulatory filings in the MCS category in Europe by 2026. The commercial rights for both FCS and MCS remain with Sobi, excluding the United States, Canada, and China, where the company is pursuing additional opportunities.
Conclusion: A Positive Trajectory
Sobi consistently illustrates a trajectory of growth and adaptability within the rare disease biopharmaceutical sector. By upgrading its forecasts and maintaining a focus on its core values of transparency and accountability, Sobi is well-positioned to navigate challenges and capitalize on emerging opportunities.
Frequently Asked Questions
What was the revised outlook for Sobi for 2025?
Sobi revised its 2025 outlook to anticipate revenue growth of a low double-digit percentage, an upgrade from a high single-digit projection.
When will Sobi's Q3 financial report be published?
The Q3 financial report will be published on October 20, 2025, at 08:00 AM CEST.
What drove the revenue growth in Q3 2025?
The revenue growth in Q3 2025 was primarily driven by the strong performance of Sobi products like Altuvoct, Doptelet, and Gamifant.
What is the significance of Vonjo for Sobi?
Vonjo is considered a long-term growth driver for Sobi, despite an impairment charge recorded in Q3 2025.
What are the future plans for Tryngolza?
Sobi plans to file for regulatory approval for Tryngolza in multifactorial chylomicronemia syndromes in Europe in 2026.
